Sitemap
June 17, 2020 Articles
Filter by Available Specialty
- ‘Let doctors be doctors’: New AMA president discusses priorities
- 1 in 10 patients continue prescription opioid use long after cardiac surgery
- Absolute PASI thresholds maintained after certolizumab pegol for plaque psoriasis
- Acalabrutinib produces durable remissions, long-term tolerability in treatment-naive CLL
- American Thoracic Society calls for moratorium on tear gas use during COVID-19 pandemic
- Anterior, posterior approaches for outpatient THA yielded similar outcomes
- Anti-CD19 CAR-T cells trigger durable remissions of CLL, B-cell lymphoma
- Azithromycin confers twofold greater 5-day CV mortality risk vs. amoxicillin
- BLOG: COVID — three immediate action steps
- Children’s Hospital Colorado ranked top hospital for pediatric GI, GI surgery
- CHOW NOW
- CPX-351 produces long-term remission in older patients with AML
- DFN-15 safe, effective in episodic migraine
- ENCORE-VT
- Endocrine Society holds vigil, moment of silence for racial injustice
- Fasting guidelines may not affect procedural sedation, complications in pediatric patients
- FDA approves biosimilar insulin glargine
- FDA approves Keytruda for tumor mutational burden-high solid tumors
- FDA expands approval of secukinumab for nonradiographic axial spondyloarthritis
- FDA grants fast track designation to Onivyde for advanced pancreatic cancer
- FDA warns MediNatura against 'potentially toxic' homeopathic injectables for joint disease
- From words to actions to change: How medicine, academia can respond to racial injustice
- Gemtuzumab ozogamicin plus venetoclax shows promise in relapsed, refractory AML
- Hard-to-treat multiple myeloma responds to novel CELMoD agent
- Higher BMI may benefit survival in myeloma
- How did rheumatology wind up in the cytokine storm?
- Infective endocarditis confers poor outcomes after TAVR
- Intravitreal injections of anti-HtrA1 well tolerated in patients with geographic atrophy
- Ixazomib maintenance prolongs PFS in non-ASCT multiple myeloma
- LATIN
- Novel drugs, new targets expand options for lipid management
- ODYSSEY HoFH
- Older age, diabetes prolong onychomycosis cure
- Ophthalmic societies protest use of rubber bullets, tear gas on citizens
- P2X3 receptor antagonist shows promise for treatment of refractory chronic cough
- Patient-reported outcomes may predict overall survival in AML
- Pembrolizumab improves PFS vs. brentuximab vedotin in classical Hodgkin lymphoma
- Phase 2 trial to assess natural killer cell therapy regimen for advanced pancreatic cancer
- Phase 2 trial to assess natural killer cell therapy regimen for advanced pancreatic cancer
- PHQ-2 screening followed by PHQ-9 may provide accurate depression detection
- PRAETORIAN
- PRONOMOS
- PROs better for measuring toxicities than patient satisfaction
- Q&A: Hospitalization fears in US common amid COVID-19 pandemic
- Q&A: Should children be included in COVID-19 vaccine trials?
- Rapid steroid tapering appears safe in myeloma treated with daratumumab
- Selinexor could be new ‘backbone’ in myeloma treatment
- Shelter from the cytokine storm: The changing role for rheumatology in COVID-19
- Simulation-based study shows cost-effectiveness of teleretinal screening for DR
- Sleep apnea and CVD: The need for collaboration
- Specific traits among adolescents increase risk for gun use
- Substituting red meat with alternate dietary proteins may reduce kidney disease risk
- Survey reveals ‘knowledge gaps’ in coronary artery disease screening pre-kidney transplant
- Survey shows ‘clear gap’ in US tick surveillance, control
- Systematic, test-guided TB treatment result in similar outcomes
- Top in endocrinology: Highlights from American Diabetes Association meeting
- Unnecessary antibiotic prescribing decreases in ambulatory care settings over 5-year period
- VENUS
- VICTORIA
- VIDEO: ‘Significant’ findings in HER2CLIMB trial
- VIDEO: Effect of shorter time to treatment for patients in rural areas
- VIDEO: Investigational antibody-drug conjugate shows promise in breast cancer